Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Cardiology

Managing the Risk: Treatment Strategies and Options

At a Glance

The primary treatment for CPVT is a non-selective beta-blocker like nadolol to stabilize the heart's adrenaline response. Consistency is critical, as missed doses are dangerous. Flecainide or LCSD surgery may be added if needed, while ICDs are used with extreme caution due to shock storm risks.

The primary goal of treating Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is to prevent dangerous heart rhythms from ever starting. Unlike many other heart conditions where doctors might rely on a “safety net” like a defibrillator, CPVT management focuses heavily on stabilizing the heart’s internal chemistry with medication and, sometimes, surgery [1][2].

Return to the Home Page.

The Gold Standard: Nadolol

The first line of defense for almost every person with CPVT is a non-selective beta-blocker, most commonly nadolol [3][1].

  • Why Nadolol? Unlike “selective” beta-blockers (like metoprolol or atenolol), which only target the heart, non-selective beta-blockers provide a broader shield against the effects of adrenaline [3][4].
  • Stability: Nadolol stays in the body for a long time, providing a steady “brake” on the adrenaline response 24 hours a day [1][5].
  • Adherence is Critical: Because CPVT is so sensitive to adrenaline, even a single missed dose of nadolol can leave the heart unprotected [1]. Never abruptly stop taking a beta-blocker. Stopping suddenly can cause “rebound” adrenaline sensitivity, putting you at severe risk for an immediate cardiac event [1].
  • Stomach Illness Protocol: If a patient catches a stomach bug and cannot keep their medication down, this is a medical emergency. You must have a plan with your doctor—usually involving a trip to the ER for IV beta-blockers until oral medication can be tolerated [1][6].

The Dual Protector: Flecainide

If a patient continues to have abnormal heart rhythms during an Exercise Stress Test while on a beta-blocker, doctors often add flecainide [7][8].
Flecainide works in two ways [9][10]:

  1. The Stabilizer: It acts like a “weight” on the leaky Ryanodine Receptor (RyR2) gateway, helping to keep it shut during the heart’s resting phase [10][11].
  2. The Shield: It also blocks certain sodium channels, which helps prevent the electrical “glitches” that lead to dangerous rhythms [9][12].

Left Cardiac Sympathetic Denervation (LCSD)

For patients who have high-risk symptoms or cannot tolerate medications, a surgical option called LCSD may be considered [13][14].
In this procedure, a surgeon clips or removes specific nerves on the left side of the spine that carry adrenaline signals directly to the heart [15][16]. This “mutes” the heart’s response to stress without affecting your ability to be active [17][18]. It is often used as a way to avoid or delay the need for an ICD [15][19].

The Risk of ICDs: The “Shock Storm”

An Implantable Cardioverter-Defibrillator (ICD) is a device that can shock the heart back into a normal rhythm. While lifesaving in other conditions, ICDs are used with extreme caution in CPVT [20][21].

CPVT creates a dangerous paradox called the shock-pain-adrenaline cycle [22][21]:

  1. The heart enters a dangerous rhythm and the ICD delivers a powerful shock.
  2. The pain and fear of the shock cause a massive “dump” of adrenaline into the patient’s system.
  3. This surge of adrenaline causes the heart to immediately enter another dangerous rhythm.
  4. The ICD shocks again, creating more pain and more adrenaline.

This can lead to a catecholamine storm (or shock storm), where the device shocks the patient repeatedly [22][2]. Because of this risk, doctors focus on “upstream” treatments—like medication and LCSD—to prevent the need for a shock [1][23]. If an ICD is necessary, it is programmed with very specific “slow-to-shock” settings [24][22].

Pregnancy Considerations

For adult women with CPVT, pregnancy and the postpartum period bring significant hormonal and physical stress changes. Close monitoring by a high-risk maternal-fetal medicine specialist and an electrophysiologist is essential, as beta-blocker dosages may need strict adjustments throughout the pregnancy [25][13].

Common questions in this guide

Why is nadolol recommended for CPVT instead of other beta-blockers?
Nadolol is a non-selective beta-blocker, which means it provides a broader shield against adrenaline compared to targeted beta-blockers. It also stays in the body longer, offering a steady 24-hour defense against dangerous heart rhythms.
What should I do if I get a stomach bug and cannot keep my CPVT medication down?
Inability to keep your medication down is a medical emergency for CPVT patients. You must go to the emergency room to receive intravenous beta-blockers until you are able to safely tolerate your oral medication again.
How does flecainide help treat CPVT?
Flecainide is often added if beta-blockers alone do not fully control abnormal rhythms. It works by keeping the heart's calcium gateway closed during the resting phase and blocking sodium channels to prevent electrical glitches.
What is Left Cardiac Sympathetic Denervation (LCSD) surgery?
LCSD is a surgical procedure where specific nerves on the left side of the spine are clipped or removed. This mutes the adrenaline signals sent directly to the heart, reducing the heart's stress response without limiting your physical activity.
Why are implantable defibrillators (ICDs) risky for CPVT patients?
ICDs can cause a dangerous cycle in CPVT patients known as a shock storm. The pain and fear of an ICD shock cause a massive adrenaline release, which immediately triggers another dangerous heart rhythm and leads to repeated shocks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why is nadolol specifically recommended for my case instead of a more common beta-blocker like metoprolol?
  2. 2.If I get a stomach bug and vomit my medication, what is our exact emergency protocol to ensure I am protected?
  3. 3.If I am still showing 'extra beats' on my exercise test, how would flecainide help stabilize my heart's calcium gateway?
  4. 4.What are the long-term pros and cons of Left Cardiac Sympathetic Denervation (LCSD) surgery versus getting an ICD?
  5. 5.If we choose an ICD, how can we ensure it is programmed with 'slow-to-shock' settings to avoid a shock storm?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.

    Przybylski R, Abrams DJ

    Current opinion in cardiology 2023; (38(4)):390-395 doi:10.1097/HCO.0000000000001051.

    PMID: 37016946
  2. 2

    Efficacy of bilateral thoracoscopic sympathectomy in a patient with catecholaminergic polymorphic ventricular tachycardia.

    Okajima K, Kiuchi K, Yokoi K, et al.

    Journal of arrhythmia 2016; (32(1)):62-6 doi:10.1016/j.joa.2015.07.002.

    PMID: 26949433
  3. 3

    An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia.

    Peltenburg PJ, Kallas D, Bos JM, et al.

    Circulation 2022; (145(5)):333-344 doi:10.1161/CIRCULATIONAHA.121.056018.

    PMID: 34874747
  4. 4

    Compromised repolarization reserve in a murine model of catecholaminergic polymorphic ventricular tachycardia caused by RyR2-R420Q mutation.

    Zissimopoulos S, Kirilenko P, Braza-Boïls A, et al.

    Journal of molecular and cellular cardiology 2025; (206()):127-140 doi:10.1016/j.yjmcc.2025.07.014.

    PMID: 40714045
  5. 5

    Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia.

    Peltenburg PJ, van den Heuvel LM, Kallas D, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2024; (26(2)) doi:10.1093/europace/euae044.

    PMID: 38349347
  6. 6

    Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

    Vaksmann G, Klug D

    Pacing and clinical electrophysiology : PACE 2018; (41(10)):1378-1380 doi:10.1111/pace.13446.

    PMID: 29989676
  7. 7

    Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

    Bergeman AT, Lieve KVV, Kallas D, et al.

    Circulation 2023; (148(25)):2029-2037 doi:10.1161/CIRCULATIONAHA.123.064786.

    PMID: 37886885
  8. 8

    A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.

    Preininger MK, Jha R, Maxwell JT, et al.

    Disease models & mechanisms 2016; (9(9)):927-39 doi:10.1242/dmm.026823.

    PMID: 27491078
  9. 9

    The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia.

    Li Y, Peng X, Lin R, et al.

    Frontiers in physiology 2022; (13()):850117 doi:10.3389/fphys.2022.850117.

    PMID: 35356081
  10. 10

    Flecainide Specifically Targets the Monovalent Countercurrent Through the Cardiac Ryanodine Receptor, While a Dominant Opposing Ca2+/Ba2+ Current Is Present.

    Gaburjakova J, Domsicova M, Poturnayova A, Gaburjakova M

    International journal of molecular sciences 2024; (26(1)) doi:10.3390/ijms26010203.

    PMID: 39796059
  11. 11

    Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

    Salvage SC, Chandrasekharan KH, Jeevaratnam K, et al.

    British journal of pharmacology 2018; (175(8)):1260-1278 doi:10.1111/bph.13807.

    PMID: 28369767
  12. 12

    Mechanisms of flecainide induced negative inotropy: An in silico study.

    Yang PC, Giles WR, Belardinelli L, Clancy CE

    Journal of molecular and cellular cardiology 2021; (158()):26-37 doi:10.1016/j.yjmcc.2021.05.007.

    PMID: 34004185
  13. 13

    Thoracoscopic Left Cardiac Sympathetic Denervation for a Patient with Catecholaminergic Polymorphic Ventricular Tachycardia and Recurrent Implantable Cardioverter-Defibrillator Shocks.

    Yu WS, Kim TH, Suh JW, et al.

    The Korean journal of thoracic and cardiovascular surgery 2015; (48(3)):220-4 doi:10.5090/kjtcs.2015.48.3.220.

    PMID: 26078933
  14. 14

    Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.

    Imberti JF, Underwood K, Mazzanti A, Priori SG

    Heart, lung & circulation 2016; (25(8)):777-83.

    PMID: 26948768
  15. 15

    Optimizing Peri-Operative Pain Management in Children With Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia Undergoing Left Cardiac Sympathetic Denervation: A Case Series on Continuous Erector Spinae Plane Block and Serratus Plane Block.

    Mossetti V, Di Corrado R, HaxhiNasto H, et al.

    Paediatric anaesthesia 2026; (36(2)):173-180 doi:10.1111/pan.70075.

    PMID: 41195781
  16. 16

    Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.

    De Ferrari GM, Dusi V, Spazzolini C, et al.

    Circulation 2015; (131(25)):2185-93 doi:10.1161/CIRCULATIONAHA.115.015731.

    PMID: 26019152
  17. 17

    The Effect of Left Cardiac Sympathetic Denervation on Exercise in Patients With Long QT Syndrome.

    Anderson HN, Bos JM, Rohatgi RK, Ackerman MJ

    JACC. Clinical electrophysiology 2019; (5(9)):1084-1090 doi:10.1016/j.jacep.2019.06.008.

    PMID: 31537339
  18. 18

    Quality of life after videoscopic left cardiac sympathetic denervation in patients with potentially life-threatening cardiac channelopathies/cardiomyopathies.

    Antiel RM, Bos JM, Joyce DD, et al.

    Heart rhythm 2016; (13(1)):62-9.

    PMID: 26341607
  19. 19

    The Year in Pediatric Electrophysiology: 2021.

    von Alvensleben JC, Collins KK

    The Journal of innovations in cardiac rhythm management 2022; (13(1)):4825-4828 doi:10.19102/icrm.2022.130111.

    PMID: 35127234
  20. 20

    Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.

    van der Werf C, Lieve KV, Bos JM, et al.

    European heart journal 2019; (40(35)):2953-2961 doi:10.1093/eurheartj/ehz309.

    PMID: 31145795
  21. 21

    Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review.

    Roston TM, Jones K, Hawkins NM, et al.

    Heart rhythm 2018; (15(12)):1791-1799 doi:10.1016/j.hrthm.2018.06.046.

    PMID: 30063211
  22. 22

    Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance.

    Giudicessi JR, Lieve KVV, Rohatgi RK, et al.

    Circulation. Genomic and precision medicine 2019; (12(5)):e002510 doi:10.1161/CIRCGEN.119.002510.

    PMID: 31112425
  23. 23

    Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.

    Wangüemert Pérez F, Hernández Afonso JS, Groba Marco MDV, et al.

    Revista espanola de cardiologia (English ed.) 2018; (71(3)):185-191 doi:10.1016/j.rec.2017.04.032.

    PMID: 28789916
  24. 24

    [Ventricular arrhythmias in ion channel diseases].

    Wolpert C, Vogel M, Nagel C, et al.

    Herzschrittmachertherapie & Elektrophysiologie 2017; (28(2)):169-176 doi:10.1007/s00399-017-0510-6.

    PMID: 28534204
  25. 25

    Advances in the Molecular Genetics of Catecholaminergic Polymorphic Ventricular Tachycardia.

    Song J, Luo Y, Jiang Y, He J

    Frontiers in pharmacology 2021; (12()):718208 doi:10.3389/fphar.2021.718208.

    PMID: 34483927

This page provides educational information about CPVT treatment options. Always consult your electrophysiologist or cardiologist before making any changes to your medication or treatment plan.

Get notified when new evidence is published on Catecholaminergic polymorphic ventricular tachycardia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.